UT-MD Anderson Cancer Center: Response-Adapted Ultra-Low Dose Radiation Achieves Complete Response In 90% Of Patients With Orbital Indolent B-Cell Lymphomas
October 25, 2022
October 25, 2022
HOUSTON, Texas, Oct. 25 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Oct. 23, 2022:
* * *
Results from MD Anderson-led Phase II trial presented at ASTRO 2022
* * *
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymph . . .
* * *
Results from MD Anderson-led Phase II trial presented at ASTRO 2022
* * *
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymph . . .